Tag Archives: pharmaceutical
Biotech drugs: Pushing policy boundaries
Since the passage of the Medicare prescription drug benefit (Part D), Medicare policy and pricing decisions have taken on a role normally assigned to the market: the ongoing challenge to balance access considerations, the role and strength of evidence for efficacy and safety, and the cost of new treatments. Biotech medicines are under the spotlight for a number of reasons. Continue reading
Hatch-Waxman 25 years later…lots o’ (the same) cheap drugs
25 years on, was Hatch-Waxman such a great idea? Dried-up small-molecule pipelines, the endless search for blockbusters at the expense of innovation, in-licensing from smaller innovative companies–just what you’d expect from a law that had the unintended effect of shutting down innovation. Continue reading
Filed under Pharmaceutical legislation
